Statin safety project: open for out-licensing and/or co-depelopment
- We have previously shown that statins interfere with the endogenous cardioprotective mechanism of pre- and postconditioning, thereby producing an occult cardiotoxicity (Am J Physiol Heart Circ Physiol. 294:H2406-9, 2008; Pharmacol Rev, 59:418-58, 2007)
Summary of invention:
- Endogenous substance to inhibit a side effect of statins to reduce endogenous cardioprotection.
- Patented technology (primary filing date May, 2012)
Potential investors and/or co-development partners,
please contact us for further details at
(Please manually type the e-mail address in your e-mail client.)